Literature DB >> 21052729

Minimal change disease: a "two-hit" podocyte immune disorder?

Michiko Shimada1, Carlos Araya, Chris Rivard, Takuji Ishimoto, Richard J Johnson, Eduardo H Garin.   

Abstract

Minimal change disease (MCD) is the most common nephrotic syndrome in children and is commonly thought to be a T-cell disorder mediated by a circulating factor that alters podocyte function resulting in massive proteinuria. We suggest that MCD is a "two-hit" disorder. As originally hypothesized by Reiser et al. in 2004, we propose that the initial hit is the induction of CD80 (also known as B7.1) on the podocyte, and that this results in an alteration in shape with actin rearrangement that alters glomerular permeability and causes proteinuria. We propose that CD80 expression may result from either direct binding of the podocyte by cytokines from activated T cells or by activation of podocyte toll-like receptors (TLR) by viral products or allergens. We further hypothesize that under normal circumstances, CD80 expression is only transiently expressed and proteinuria is minimal due to rapid autoregulatory response by circulating T regulatory cells or by the podocyte itself, probably due to the expression of factors [cytotoxic T-lymphocyte-associated (CTLA)-4, interleukin (IL)-10, and possibly transforming growth factor (TGF)-β] that downregulate the podocyte CD80 response. In MCD, however, there is a defect in CD80 podocyte autoregulation. This results in persistent CD80 expression and persistent proteinuria. If correct, this hypothesis may lead to both new diagnostic tests and potential therapeutics for this important renal disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052729     DOI: 10.1007/s00467-010-1676-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  32 in total

Review 1.  Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome.

Authors:  Jochen Reiser; Peter Mundel
Journal:  J Am Soc Nephrol       Date:  2004-09       Impact factor: 10.121

2.  Allergy and lipoid nephrosis.

Authors:  G Lagrue; J Laurent
Journal:  Adv Nephrol Necker Hosp       Date:  1983

3.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

4.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors:  Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2006-11-15       Impact factor: 19.103

5.  Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome.

Authors:  Wai Cheung; Chang-Li Wei; Ching-Ching Seah; Stanley C Jordan; Hui-Kim Yap
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

Review 6.  Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide.

Authors:  Richard J Johnson; Abdias Hurtado; Justin Merszei; Bernardo Rodriguez-Iturbe; Lili Feng
Journal:  Am J Kidney Dis       Date:  2003-09       Impact factor: 8.860

Review 7.  Interleukin-10: new perspectives on an old cytokine.

Authors:  David M Mosser; Xia Zhang
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

Review 8.  Idiopathic nephrotic syndrome and atopy: is there a common link?

Authors:  Maher Abdel-Hafez; Michiko Shimada; Pui Y Lee; Richard J Johnson; Eduardo H Garin
Journal:  Am J Kidney Dis       Date:  2009-06-25       Impact factor: 8.860

9.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Authors:  Mónica Vigna-Perez; Berenice Hernández-Castro; Octavio Paredes-Saharopulos; Diana Portales-Pérez; Lourdes Baranda; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  Arthritis Res Ther       Date:  2006-05-05       Impact factor: 5.156

10.  Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis.

Authors:  Caroline I Sellin; Jean-François Jégou; Joëlle Renneson; Johan Druelle; T Fabian Wild; Julien C Marie; Branka Horvat
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

View more
  35 in total

1.  Dosing of glucocorticosteroids in nephrotic syndrome.

Authors:  Otto Mehls; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2011-09-09       Impact factor: 3.714

2.  Urine and serum ghrelin, sCD80 and sCTLA-4 levels in doxorubicin-induced experimental nephrotic syndrome.

Authors:  Duygu Ozkorucu; Nuran Cetin; Nadide Melike Sav; Bilal Yildiz
Journal:  Int Urol Nephrol       Date:  2016-02-27       Impact factor: 2.370

Review 3.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

4.  Urinary CD80 levels as a diagnostic biomarker of minimal change disease.

Authors:  Chen Ling; Xiaorong Liu; Ying Shen; Zhi Chen; Jianfeng Fan; Yeping Jiang; Qun Meng
Journal:  Pediatr Nephrol       Date:  2014-08-21       Impact factor: 3.714

5.  Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus.

Authors:  Seo Rin Kim; Soo Bong Lee; Il Young Kim; Dong Won Lee; Harin Rhee; Eun Young Seong; Sang Heon Song; Ihm Soo Kwak
Journal:  Clin Exp Nephrol       Date:  2011-11-25       Impact factor: 2.801

6.  LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile.

Authors:  Tarak Srivastava; Mukut Sharma; Kok-Hooi Yew; Ram Sharma; R Scott Duncan; Moin A Saleem; Ellen T McCarthy; Alexander Kats; Patricia A Cudmore; Uri S Alon; Christopher J Harrison
Journal:  J Cell Commun Signal       Date:  2012-11-17       Impact factor: 5.782

7.  Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.

Authors:  Eduardo H Garin; Jochen Reiser; Gabriel Cara-Fuentes; Changli Wei; Dany Matar; Heiman Wang; Nada Alachkar; Richard J Johnson
Journal:  Pediatr Nephrol       Date:  2014-09-20       Impact factor: 3.714

Review 8.  Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.

Authors:  Valéry Elie; May Fakhoury; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2011-06-28       Impact factor: 3.714

Review 9.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

10.  Increased risk of idiopathic nephrotic syndrome in children with atopic dermatitis.

Authors:  Chang-Ching Wei; Jeng-Dau Tsai; Cheng-Li Lin; Te-Chun Shen; Tsai-Chung Li; Chi-Jung Chung
Journal:  Pediatr Nephrol       Date:  2014-07-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.